BR112022018819A2 - Vacinas contra coronavírus e métodos de uso - Google Patents

Vacinas contra coronavírus e métodos de uso

Info

Publication number
BR112022018819A2
BR112022018819A2 BR112022018819A BR112022018819A BR112022018819A2 BR 112022018819 A2 BR112022018819 A2 BR 112022018819A2 BR 112022018819 A BR112022018819 A BR 112022018819A BR 112022018819 A BR112022018819 A BR 112022018819A BR 112022018819 A2 BR112022018819 A2 BR 112022018819A2
Authority
BR
Brazil
Prior art keywords
methods
vaccines against
against coronavirus
coronavirus
vaccines
Prior art date
Application number
BR112022018819A
Other languages
English (en)
Portuguese (pt)
Inventor
B Gaynor Richard
Srinivasan Lakshmi
PORAN Asaf
Harjanto Dewi
Kuksin Christina
Abram Rothenberg Daniel
Srouji John
Original Assignee
Biontech Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc filed Critical Biontech Us Inc
Publication of BR112022018819A2 publication Critical patent/BR112022018819A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112022018819A 2020-03-20 2021-03-19 Vacinas contra coronavírus e métodos de uso BR112022018819A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062992666P 2020-03-20 2020-03-20
US202063026559P 2020-05-18 2020-05-18
US202063059582P 2020-07-31 2020-07-31
US202063086519P 2020-10-01 2020-10-01
US202063122904P 2020-12-08 2020-12-08
PCT/US2021/023267 WO2021188969A2 (en) 2020-03-20 2021-03-19 Coronavirus vaccines and methods of use

Publications (1)

Publication Number Publication Date
BR112022018819A2 true BR112022018819A2 (pt) 2022-11-29

Family

ID=77771752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018819A BR112022018819A2 (pt) 2020-03-20 2021-03-19 Vacinas contra coronavírus e métodos de uso

Country Status (11)

Country Link
US (2) US20230141371A1 (https=)
EP (1) EP4121104A4 (https=)
JP (1) JP2023518821A (https=)
KR (1) KR20230004508A (https=)
AU (1) AU2021237720A1 (https=)
BR (1) BR112022018819A2 (https=)
CA (1) CA3172315A1 (https=)
IL (1) IL296617A (https=)
MX (1) MX2022011671A (https=)
TW (1) TW202200199A (https=)
WO (1) WO2021188969A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
US20230184764A1 (en) * 2020-04-06 2023-06-15 The Trustees Of Columbia University In The City Of New York Peptide sequences for detection and differentiation of antibody responses to sars-cov-2 and other human corona viruses
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
US20230241202A1 (en) * 2020-05-29 2023-08-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adenovirus-Based SARS-CoV-2 Vaccine
US20230263883A1 (en) * 2020-07-08 2023-08-24 The Brigham And Women`S Hospital, Inc. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Peptide Epitopes
WO2022025264A1 (ja) * 2020-07-31 2022-02-03 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
US12247978B2 (en) * 2020-08-05 2025-03-11 Arizona Board Of Regents On Behalf Of Northern Arizona University Compositions and methods for detection and treatment of coronavirus infection
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
US12419948B2 (en) * 2020-08-31 2025-09-23 The Broad Institute, Inc. Immunogenic compositions and use thereof
WO2022051223A1 (en) * 2020-09-02 2022-03-10 The Feinstein Institutes For Medical Research Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
JP2023550094A (ja) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
JP7598538B2 (ja) 2021-01-29 2024-12-12 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
US20240192211A1 (en) * 2021-02-24 2024-06-13 Biotome Pty Ltd Peptides and their use in diagnosis of sars-cov-2 infection
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
EP4070814A1 (en) * 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
DK4319803T3 (da) 2021-04-08 2025-12-15 Vaxthera Sas Coronavirusvaccine omfattende et mosaikprotein
WO2022221189A1 (en) * 2021-04-12 2022-10-20 La Jolla Institute For Immunology Coronavirus t cell epitopes and uses thereof
WO2022268916A2 (en) * 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
WO2023044542A1 (en) * 2021-09-24 2023-03-30 The University Of Adelaide Sars cov-2 vaccine
WO2023049983A1 (en) * 2021-09-28 2023-04-06 Medicago Inc. Cpmv vlps displaying sars-cov-2 epitopes
CN113981140B (zh) * 2021-10-09 2024-02-27 广州达安基因股份有限公司 新型冠状病毒德尔塔突变株的检测方法及核酸检测试剂盒
EP4419136A1 (en) * 2021-10-21 2024-08-28 BioNTech SE Coronavirus vaccine
WO2023067193A2 (en) 2021-10-22 2023-04-27 BioNTech SE Compositions for administration of different doses of rna
US20250295755A1 (en) 2021-10-22 2025-09-25 Sail Biomedicines, Inc. Mrna vaccine composition
WO2023096896A2 (en) * 2021-11-23 2023-06-01 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
CA3238764A1 (en) 2021-11-23 2023-06-01 Siddharth Patel A bacteria-derived lipid composition and use thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4445906A1 (en) * 2021-12-08 2024-10-16 Anda Biology Medicine Development (Shenzhen) Co., Ltd. Antigenic polypeptide and use thereof
EP4452239A1 (en) 2021-12-20 2024-10-30 Sail Biomedicines, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
CN114686620B (zh) * 2022-01-21 2024-05-07 生物岛实验室 新型冠状病毒多种变异株核酸质谱检测的引物组合、试剂盒及检测方法
CN114729373B (zh) * 2022-01-27 2023-01-31 深圳市瑞吉生物科技有限公司 一种新型冠状病毒mRNA疫苗及其制备方法与应用
EP4469079A1 (en) * 2022-01-28 2024-12-04 Pfizer Inc. Coronavirus antigen variants
WO2023147091A1 (en) * 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
AU2023219116A1 (en) * 2022-02-08 2024-08-15 Iowa State University Research Foundation, Inc. Mrna expression and delivery systems
GB202201768D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Peptides
EP4486375A1 (en) * 2022-03-02 2025-01-08 ISR Immune System Regulation Holding AB (publ) Vaccine composition comprising an antigen and a tlr3 agonist
CN116768988A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
CN114907454A (zh) * 2022-04-08 2022-08-16 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的N蛋白多肽
CN114907453B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽
WO2023213990A1 (en) 2022-05-05 2023-11-09 Etherna Immunotherapies Nv Multi-epitope construct
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
LU103079B1 (en) * 2023-02-28 2024-08-28 PMCR GmbH IMMUNIZATION AGAINST VIRAL INFECTIONS DISEASE(S)
EP4631527A1 (en) * 2022-12-09 2025-10-15 Seoul National University R&DB Foundation Nanoparticle comprising peptide-based conjugate for delivering mrna into b cell and t cell and uses thereof
EP4631528A1 (en) * 2022-12-09 2025-10-15 Nibec Co., Ltd. Nanoparticle comprising peptide-based conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
JP2026501447A (ja) * 2022-12-16 2026-01-15 ジーニアス・バイオテクノロジー・インコーポレイテッド 多重抗原性ｒｎａ ｓａｒｓ－ｃｏｖ－２ワクチン及び関連する方法
PL443854A1 (pl) * 2023-02-22 2024-08-26 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
EP4676530A2 (en) * 2023-03-06 2026-01-14 Vakston, Inc. Nucleocapsid antigen immunotherapy for covid-19 fusion proteins and methods of use
WO2024263826A1 (en) * 2023-06-22 2024-12-26 Modernatx, Inc. Sars-cov-2 t cell vaccines
WO2025101631A2 (en) * 2023-11-07 2025-05-15 BioNTech SE Compositions and methods for preparing vaccines
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
CN118955657B (zh) * 2024-01-09 2025-03-04 中山大学 一种特异性表位多肽及其试剂盒和应用
WO2025164815A1 (ko) * 2024-01-29 2025-08-07 주식회사 나이벡 안지오텐신전환효소 2(ace2)에 대한 결합능이 있는 신규한 펩타이드 및 이의 용도
CN119144611A (zh) * 2024-09-19 2024-12-17 宁夏农林科学院枸杞科学研究所 黑果枸杞LrCHS2基因及其编码蛋白在促进枸杞花青素生物合成中的应用
CN120081914A (zh) * 2025-01-03 2025-06-03 中国人民解放军军事科学院军事医学研究院 一种HLA-C限制性SARS-CoV-2淋巴细胞抗原表位肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
US20050106563A1 (en) * 2003-09-08 2005-05-19 Genesis Biotech Inc. Epitope profiles of SARS coronavirus
CN100408595C (zh) * 2003-12-31 2008-08-06 第二军医大学免疫学研究所 Sars病毒hla-a2限制性表位多肽及其应用
CN101085812B (zh) * 2006-06-08 2010-12-01 中国科学院上海生命科学研究院 一种sars冠状病毒多肽抗原及其应用
JP5686370B2 (ja) * 2008-11-28 2015-03-18 日油株式会社 Ｓａｒｓコロナウイルスの細胞傷害性ｔ細胞エピトープペプチド及びその用途
BR112014013745B1 (pt) * 2011-12-09 2022-06-14 Institut Pasteur Método de teste in vitro, kit de detecção e seu uso, método in vitro de diagnóstico, método de fabricação de kit, e teste de imunosseleção multiplex
EP3325646B1 (en) * 2015-07-22 2020-08-19 F.Hoffmann-La Roche Ag Identification of antigen epitopes and immune sequences recognizing the antigens

Also Published As

Publication number Publication date
WO2021188969A2 (en) 2021-09-23
KR20230004508A (ko) 2023-01-06
MX2022011671A (es) 2023-01-24
CA3172315A1 (en) 2021-09-23
EP4121104A4 (en) 2025-12-17
EP4121104A2 (en) 2023-01-25
US20230083931A1 (en) 2023-03-16
JP2023518821A (ja) 2023-05-08
US20230141371A1 (en) 2023-05-11
IL296617A (en) 2022-11-01
AU2021237720A1 (en) 2022-11-17
WO2021188969A3 (en) 2021-11-25
TW202200199A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
BR112023020600A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
BR112022023013A2 (pt) Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
EP3947475A4 (en) CORONAVIRUS VACCINE COMPOSITIONS, METHODS AND USES THEREOF
MX2024010591A (es) Compuestos y metodos para el tratamiento de infecciones virales.
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
MX2020009095A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
BR112022017240A2 (pt) Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório
MX2021015448A (es) Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas.
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
WO2022013696A9 (en) Recombinant vaccinia virus
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
MX2020010338A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
PH12017550047B1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
ZA202211004B (en) 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus
BR112022021423A2 (pt) Uso de proteína surfactante d para tratar infecções virais
JOP20240233A1 (ar) بروتينات cd24 الطافرة واستخداماتها للوقاية من السرطان وعلاجه

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIONTECH SE (DE)